Man Who Predicted Bitcoin Says "This is Bigger"
He called Tesla in 2018... and Bitcoin in 2015... now he says a brand-new financial technology could unleash a Quadrillion-dollar impact starting 2021.
Learn More Here!
John Dobak, insider at DermTech

John Dobak Insider Information

CEO of DermTech
John Dobak, M.D. has served on our Board since the completion of the Business Combination in August 2019 and served on DermTech Operations’ board of directors between June 2012 and August 2019. Dr. Dobak has served as our Chief Executive Officer since the completion of the Business Combination in August 2019 and served as Chief Executive Officer of DermTech Operations between June 2012 and August 2019. From 2006 until 2011, Dr. Dobak served as the founder and Chief Executive Officer of Lithera, Inc., a pharmaceutical company developing an injectable product for dermatology. Dr. Dobak is the founder and President of the JAKK Group, a life sciences technology accelerator, which has created several companies including Lithera, Inc., INNERCOOL Therapies, Inc., CryoGen, Inc., and CryoCor, Inc. Dr. Dobak’s companies have developed and marketed therapeutics devices for endovascular hypothermia, cryosurgical cardiac catheters, and endometrial ablation. Dr. Dobak received a Bachelor’s Degree from the University of California, Los Angeles and a Medical Doctorate from the University of California, San Diego. Dr. Dobak is qualified to serve on our Board because of his service as DermTech Operations’ Chief Executive Officer, his service as a member of DermTech Operations’ board of directors and his experience founding and operating multiple companies in the life sciences industry. Provided by Tagnifi.

What is John Dobak's net worth?

The estimated net worth of John Dobak is at least $15.51 million as of September 13th, 2021. Dr. Dobak owns 453,645 shares of DermTech stock worth more than $15,505,586 as of September 26th. This net worth estimate does not reflect any other investments that Dr. Dobak may own. Learn More.

What is John Dobak's salary?

As the CEO of DermTech, Inc., Dr. Dobak earned a total compensation package of $3,464,281.00 in 2020. Dr. Dobak earned a salary of $480,000.00, stock awards of $1,395,675.00, options awards of $1,400,849.00, non-equity compensation of $187,200.00, and other compensation of $557.00.

How do I contact John Dobak?

The corporate mailing address for Dr. Dobak and other DermTech executives is 11099 N. Torrey Pines Road Suite 100, La Jolla CA, 92037. DermTech can also be reached via phone at (858) 450-4222 and via email at [email protected]

Has John Dobak been buying or selling shares of DermTech?

In the last ninety days, John Dobak has sold $624,278.00 in DermTech stock. Most recently, John Dobak sold 1,899 shares of the business's stock in a transaction on Monday, September 13th. The shares were sold at an average price of $36.19, for a transaction totalling $68,724.81. Following the completion of the sale, the chief executive officer now directly owns 453,645 shares of the company's stock, valued at $16,417,412.55.

Who are DermTech's active insiders?

DermTech's insider roster includes John Dobak (CEO), Claudia Ibarra (COO), Scott Pancoast (Director), Enrico Picozza (Director), Kevin Sun (CFO), and Todd Wood (Insider).

Are insiders buying or selling shares of DermTech?

In the last year, DermTech insiders bought shares 3 times. They purchased a total of 433,898 shares worth mmore than $9,943,991.00. In the last year, insiders at the sold shares 39 times. They sold a total of 300,021 shares worth mmore than $11,647,331.39. The most recent insider tranaction occured on September, 13th when Todd Michael Wood Insider bought 1,126 shares worth more than $40,749.94. Insiders at DermTech own 8.0 % of the company.

Information on this page was last updated on 9/13/2021.

John Dobak Insider Trading History at DermTech

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/13/2021Sell1,899$36.19$68,724.81453,645View SEC Filing Icon  
9/8/2021Sell1,162$36.19$42,052.78View SEC Filing Icon  
7/1/2021Sell12,500$41.08$513,500.00459,647View SEC Filing Icon  
6/11/2021Sell7,651$41.08$314,303.08468,847View SEC Filing Icon  
6/8/2021Sell1,118$43.43$48,554.74476,498View SEC Filing Icon  
6/1/2021Sell2,970$40.22$119,453.40487,146View SEC Filing Icon  
5/3/2021Sell25,000$40.96$1,024,000.00499,095View SEC Filing Icon  
4/27/2021Sell25,000$51.35$1,283,750.00515,116View SEC Filing Icon  
4/12/2021Sell25,000$46.34$1,158,500.00550,773View SEC Filing Icon  
3/8/2021Sell780$50.04$39,031.20View SEC Filing Icon  
12/8/2020Sell786$11.86$9,321.96541,683View SEC Filing Icon  
9/10/2020Sell2,470$10.82$26,725.40543,379View SEC Filing Icon  
See Full Table

John Dobak Buying and Selling Activity at DermTech

This chart shows John Dobak's buying and selling at DermTech by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

DermTech Company Overview

DermTech logo
DermTech, Inc. is a genomics company in dermatology, which engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate the early detection of skin cancers, assesses inflammatory diseases, and customizes drug treatments. Its products include adhesive skin collection kit, pigmented lesion assay, nevome, and carcinome. The company was founded in 1995 and is headquartered in La Jolla, CA.
Read More

Today's Range

Now: $34.18
Low: $34.17
High: $35.84

50 Day Range

MA: $35.24
Low: $32.16
High: $38.45

2 Week Range

Now: $34.18
Low: $9.85
High: $84.49

Volume

261,616 shs

Average Volume

334,832 shs

Market Capitalization

$1.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.81
Learn to Customize Your Own Options Trading Strategy
This guide will help you evaluate and analyze your trading plan to create a custom options trading strategy tailored to your risk profile and market outlook. Learn how to take your trading to the next level.
Download your FREE Options Strategy Guide Today!
pixel